Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide for Immune Restoration in CLL
NCT02371577Phase 2Withdrawn
- Sponsor
- University of California, San Diego
- Start
- Feb 2017
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenalidomide in chronic lymphocytic leukemia (CLL), secondary immunodeficiency (SID), sponsored by University of California, San Diego. Planned start Feb 2017; status: withdrawn.
02
Drugs
lenalidomide
03
Conditions
chronic lymphocytic leukemia (CLL)secondary immunodeficiency (SID)
Beyond the preview
Go deeper on NCT02371577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02371577.